Related Experiment Videos
Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors
1Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA. vpuduval@mdanderson.org
Abstract:
The poor prognosis of patients with malignant brain tumors in spite of aggressive multimodality therapy has led to the search for novel therapeutic strategies. Among the targets for such treatment approaches, tumor angiogenesis has captured the attention of not only the medical field but also of the lay public because of its conceptual departure from traditional methods of cancer therapy. Angiogenesis and vascular proliferation are particularly important in the growth and progression of malignant gliomas and are used as indicators of the degree of malignancy. Recent studies have helped us gain a better understanding of the molecular mediators of this process. It is now evident that after the initial formation of malignancy the continued growth of a glioma is critically dependent on its angiogenic potential. Hence, several approaches to control angiogenesis are being developed and tested. In the present review, we examine some of these approaches from a therapeutic perspective and summarize the findings from early human trials of such agents.
Insights
Targeting tumor angiogenesis offers a novel therapeutic strategy for malignant brain tumors. This review explores anti-angiogenesis approaches and early human trial findings for glioma treatment.
Area of Science:
- Oncology
- Vascular Biology
- Neuro-oncology
Background:
- Malignant brain tumors, particularly gliomas, have a poor prognosis despite aggressive treatments.
- Tumor angiogenesis, the formation of new blood vessels, is crucial for glioma growth and malignancy.
- Understanding molecular mediators of angiogenesis is key to developing new therapies.
Purpose of the Study:
- To review therapeutic strategies targeting tumor angiogenesis in malignant brain tumors.
- To examine the role of angiogenesis in glioma progression.
- To summarize findings from early human trials of anti-angiogenesis agents.
Main Methods:
- Review of current literature on tumor angiogenesis and therapeutic approaches.
- Analysis of molecular mediators involved in glioma angiogenesis.
- Summary of results from early-phase clinical trials of anti-angiogenesis agents.
Main Results:
- Angiogenesis is a critical factor in the continued growth of malignant gliomas.
- Several therapeutic approaches to control tumor angiogenesis are under development.
- Early human trials are evaluating the efficacy and safety of these novel agents.
Conclusions:
- Targeting tumor angiogenesis represents a promising novel therapeutic strategy for malignant brain tumors.
- Further research and clinical trials are needed to optimize anti-angiogenesis therapies for gliomas.
- Controlling angiogenesis may improve outcomes for patients with malignant gliomas.